These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24671450)

  • 1. Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
    Goldstein S; Bates ER; Bhatt DL; Cao C; Holmes D; Kupfer S; Martinez F; Spaeder J; Weitz JI; Ye Z; Zannad F;
    Thromb Haemost; 2014 Jun; 111(6):1141-52. PubMed ID: 24671450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
    Weitz JI; Cao C; Eriksson BI; Fisher W; Kupfer S; Raskob G; Spaeder J; Turpie AG
    Thromb Haemost; 2010 Dec; 104(6):1150-7. PubMed ID: 20886185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
    Mega JL; Braunwald E; Murphy SA; Plotnikov AN; Burton P; Kiss RG; Parkhomenko A; Tendera M; Widimsky P; Gibson CM
    J Am Coll Cardiol; 2013 May; 61(18):1853-9. PubMed ID: 23500262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
    Mega JL; Braunwald E; Mohanavelu S; Burton P; Poulter R; Misselwitz F; Hricak V; Barnathan ES; Bordes P; Witkowski A; Markov V; Oppenheimer L; Gibson CM;
    Lancet; 2009 Jul; 374(9683):29-38. PubMed ID: 19539361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
    Lip GY; Halperin JL; Petersen P; Rodgers GM; Pall D; Renfurm RW
    J Thromb Haemost; 2015 Aug; 13(8):1405-13. PubMed ID: 26052866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
    Obonska K; Navarese EP; Lansky A; Tarantini G; Rossini R; Kozinski M; Musumeci G; Di Pasquale G; Górny B; Szczesniak A; Kowalewski M; Gurbel PA; Kubica J
    Atherosclerosis; 2013 Aug; 229(2):482-8. PubMed ID: 23672879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).
    Mega JL; Braunwald E; Wiviott SD; Murphy SA; Plotnikov A; Gotcheva N; Ruda M; Gibson CM
    Am J Cardiol; 2013 Aug; 112(4):472-8. PubMed ID: 23711804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
    Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
    Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban in patients with a recent acute coronary syndrome.
    Mega JL; Braunwald E; Wiviott SD; Bassand JP; Bhatt DL; Bode C; Burton P; Cohen M; Cook-Bruns N; Fox KA; Goto S; Murphy SA; Plotnikov AN; Schneider D; Sun X; Verheugt FW; Gibson CM;
    N Engl J Med; 2012 Jan; 366(1):9-19. PubMed ID: 22077192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
    Krantz MJ; Kaul S
    J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
    Korjian S; Braunwald E; Daaboul Y; Mi M; Bhatt DL; Verheugt FWA; Cohen M; Bode C; Burton P; Plotnikov AN; Gibson CM
    Am J Cardiol; 2018 Dec; 122(11):1896-1901. PubMed ID: 30340765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
    Gibson CM; Chakrabarti AK; Mega J; Bode C; Bassand JP; Verheugt FW; Bhatt DL; Goto S; Cohen M; Mohanavelu S; Burton P; Stone G; Braunwald E;
    J Am Coll Cardiol; 2013 Jul; 62(4):286-90. PubMed ID: 23602776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.